<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-129305</identifier>
<setSpec>0210-5705</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Immune-mediated inflammatory diseases in patients with inflammatory bowel disease. Baseline data from the Aquiles study</dc:title>
<dc:description xml:lang="en">OBJECTIVE: To determine the prevalence of immune-mediated inflammatory diseases (IMID) in a cohort of patients with inflammatory bowel disease(IBD) enrolled in hospital gastroenterology outpatients units for the AQUILES study, a prospective 2-year follow-up study. MATERIAL AND METHODS: We included patients &amp;#8805;18 years old with a prior or new diagnosis of IBD (Crohn disease [CD], ulcerative colitis [UC] or indeterminate colitis). Diagnoses were collected in a cross-sectional manner from the clinical records at enrollment of a new patient in the study. RESULTS: We included 526 patients (mean age 40.2 years; 47.3% men, 52.7% women), 300 with CD (57.0%), 218 with UC (41.4%) and 8 with indeterminate colitis. Other types of IMID were present in 71 patients (prevalence: 13.5%, 95% CI: 10.8-16.7): 47 were spondyloarthropathies (prevalence: 8.9%); 18 psoriasis (3.4%); 5 pyoderma gangrenosum (1.0%), and 11 uveitis (2.1%). The prevalence of IMID was higher in patients with CD than in those with UC (17.0% [95% CI: 13.2-21.7] vs 9.2% [95% CI: 6.0-13.8], p=0.011). In the multivariate analysis, the variables associated with the presence of IMID were diagnosis of CD (OR=1.8 [95% CI: 1.1-3.2]) and duration of IBD &amp;#8805;4 years (OR=2.1 [95% CI: 1.1-4.1] in those with disease duration 4-8 years, and OR=2.1 [95% CI: 1.2-3.9] in those with &amp;#8805;8 years vs. &lt;4 years).CONCLUSIONS: In the cohort of patients with IBD in the AQUILES study, 13.5% had another IMID, with a higher prevalence in patients with CD and&gt;4 years since disease onset (AU)</dc:description>
<dc:creator>Lázaro Pérez Calle, José</dc:creator>
<dc:creator>Tabernero, Susana</dc:creator>
<dc:creator>Cea-Calvo, Luis</dc:creator>
<dc:creator>Vanaclocha, Francisco</dc:creator>
<dc:creator>Marín-Jiménez, Ignacio</dc:creator>
<dc:creator>García-Vicuña, Rosario</dc:creator>
<dc:creator>Gisbert, Javier P</dc:creator>
<dc:creator>Juliá, Berta</dc:creator>
<dc:creator>Gordillo Ábalos, Jordi</dc:creator>
<dc:creator>Romero, Cristina</dc:creator>
<dc:creator>García Sánchez, Valle</dc:creator>
<dc:creator>Luján, Marisol</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Objetivo: Determinar la prevalencia de enfermedades inflamatorias mediadas por inmunidad (EIMI) en una cohorte de pacientes con enfermedad inflamatoria intestinal (EII) reclutada en consultas hospitalarias de aparato digestivo para el estudio Aquiles, un estudio prospectivo de 2 años de seguimiento. Material y métodos Se incluyeron pacientes de &amp;#8805; 18 años con diagnóstico previo o nuevo de EII (enfermedad de Crohn [EC], colitis ulcerosa [CU] o colitis indeterminada). Los diagnósticos se recogieron de forma transversal de la historia clínica en el momento de incorporar a cada paciente al estudio. Resultados Se incluyeron 526 pacientes (edad media 40,2 años; 47,3% hombres, 52,7% mujeres), 300 con EC (57,0%), 218 con CU (41,4%) y 8 colitis indeterminada. Presentaron otra EIMI 71 pacientes (prevalencia: 13,5%, IC 95%: 10,8-16,7): 47 fueron espondiloartritis (prevalencia: 8,9%); 18 psoriasis (3,4%); 5 pioderma gangrenoso (1,0%) y 11 uveítis (2,1%). La prevalencia de EIMI fue mayor en pacientes con EC respecto a pacientes con CU (17,0% [IC 95%: 13,2-21,7] frente a 9,2% [IC 95%: 6,0-13,8], p = 0,011). En el análisis multivariante, las variables asociadas a la presencia de EIMI fueron el diagnóstico de EC (OR = 1,8 [IC 95%: 1,1-3,2]) y un tiempo de evolución de la EII &amp;#8805; 4 años (OR = 2,1 [IC 95%: 1,1-4,1] en aquellos con 4-8 años, y OR = 2,1 [IC 95%: 1,2-3,9] en los de &amp;#8805; 8 años frente a &lt; 4 años). Conclusiones: En la cohorte de pacientes con EII del estudio Aquiles, el 13,5% presentó otra EIMI, con una prevalencia mayor en pacientes con EC y &gt; 4 años de evolución de la enfermedad (AU)</dc:description>
<dc:source>Gastroenterol Hepatol;37(9): 495-502, nov. 2014. ilus, tab</dc:source>
<dc:identifier>ibc-129305</dc:identifier>
<dc:title xml:lang="es">Enfermedades inflamatorias mediadas por inmunidad en pacientes con enfermedad inflamatoria intestinal. Datos basales del estudio Aquiles</dc:title>
<dc:subject>^d23971^s22038</dc:subject>
<dc:subject>^d7426^s22038</dc:subject>
<dc:subject>^d28607</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d23973^s22038</dc:subject>
<dc:subject>^d23695^s22038</dc:subject>
<dc:subject>^d24572</dc:subject>
<dc:type>article</dc:type>
<dc:date>201411</dc:date>
</metadata>
</record>
</ibecs-document>
